Carisma anticipates that its cash and cash equivalents of $56.5 million as of March 31, 2024, combined with the expected cost savings from implementing the revised operating plan, are sufficient to sustain its planned operations into the third quarter of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics appoints Eugene Kennedy as Chief Medical Officer
- Carisma Therapeutics initiated with a Buy at BTIG
- Carisma Therapeutics price target lowered to $9 from $11 at H.C. Wainwright
- Carisma Therapeutics’ Compliance Hurdle: Navigating Anti-Kickback and Fraud Laws in the Pharmaceutical Landscape
- Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results